Comparing SG&A Expenses: Pfizer Inc. vs Veracyte, Inc. Trends and Insights

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals and diagnostics, understanding financial trends is crucial. From 2014 to 2023, Pfizer Inc. and Veracyte, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Pfizer, a pharmaceutical giant, consistently reported SG&A expenses around $14 billion annually, with a notable dip in 2020, likely due to pandemic-related adjustments. In contrast, Veracyte, a smaller diagnostics company, saw its SG&A expenses grow from approximately $40 million in 2014 to nearly $184 million in 2023, marking a staggering increase of over 350%. This growth reflects Veracyte's expanding market presence and investment in operational capabilities. The data highlights the contrasting scales and growth strategies of these two companies, offering insights into their financial health and strategic priorities.